ImmunityBio
  • Our Science
    • Platforms
    • Pipeline
    • Expanded Access
    • Research
  • Unique Approach
    • Patients
    • Trial Investigators
    • Researchers
  • Therapies
    • Bladder Cancer
    • Glioblastoma
    • Lynch Syndrome
    • Non-Small Cell Lung Cancer
    • Pancreatic Cancer
    • COVID-19
    • HIV
  • Our Company
    • About Us
    • Investors
    • News
    • Contact
  • Careers
  • Get Started
    • Find a Trial
    • Become a Trial
      Investigator
    • License our Cells
Select Page

CD16(+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice

Jan 28, 2018 | Uncategorized

Recent Posts

  • United Nations “Unveiling the Future of Intelligent Health in Africa”
  • Piper Sandler Annual Healthcare Conference
  • LUGPA 2023 Annual Meeting
  • Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
  • Bladder Cancer Advocacy Network’s (BCAN) Annual Bladder Cancer Summit for Patients and Families

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  Twitter
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2023 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

'Nantkwest’, ‘haNK’, ‘taNK’, ’t-haNK’, ‘ceNK’, ‘NK-92’, ‘Living Drugs in a Bag’, ‘Nature’s First Responder’, ‘Outsmart Your Disease’, and ‘Smart Therapies for Difficult Diseases’ are trademarks or registered trademarks of Nantkwest, ImmunityBio, Inc.

Anktiva is a registered trademark of ImmunityBio, Inc.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap